apecasc

Avigan study fails to demonstrate benefit in COVID-19 treatment

Jul 10 , 2020. 1 hour ago – 16:02 KYODO NEWS

Supplied photo shows tablets of the anti-influenza drug Avigan. (Photo courtesy of Fujifilm)(Kyodo)

TOKYO – One of the clinical studies for the antiviral drug Avigan developed by a Japanese company failed to demonstrate a significant difference between coronavirus patients receiving the treatment and the control group, Fujita Health University which conducted the test said Friday.

Avigan, also known as favipiravir and developed by a subsidiary of Fujifilm Holdings Corp., has been seen as a possible treatment for COVID-19, the respiratory disease caused by the novel coronavirus.

CR:KYODO NEWS